Research programme: Nell1 protein therapeutics - NellOne Therapeutics
Latest Information Update: 16 Jul 2016
At a glance
- Originator NellOne Therapeutics
- Class Proteins
- Mechanism of Action NELL1 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Myocardial infarction; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (Parenteral)
- 26 Mar 2010 Preclinical trials in Wounds in USA (Parenteral)